They are nanoscopic architectures formed by the self-assembly of amphiphilic polymers . During (or after) the self-assembly process, PMs are capable to encapsulate/solubilize additional hydrophobic molecules. Several PMs formulations are already in clinical use or have been in clinical trials, for example NK911 and Genexol-PM . However, PMs often suffer from intrinsic issues such as low drug loading, instability and poor permeability across cell membranes or other biological barriers . The loading capacity (LC) and stability can directly be correlated to intrinsic properties of polymers, drugs or/and their compatibility with each other . In the past decades, poly(2-oxazoline)s (POx) and poly(2-oxazine)s (POzi) have gained significant attention for their biomedical and pharmaceutical applications . Unlike many other systems, the POx/POzi based ABA triblock copolymer (A and B, hydrophilic and hydrophobic block, respectively) have shown particular potential for development of ultra-high drug loaded micellar formulations . In particular, ABA triblock copolymers featuring poly(2-methyl-2-oxazoline) (pMeOx) as hydrophilic A block and moderately hydrophobic poly(2-n-butyl-2-oxazoline) (pBuOx), poly(2-n-butyl-2-oxazine) (pBuOzi) or poly(2-n-propyl-2-oxazoline) (pPrOx) show very promising properties such as high drug loading, excellent cytocompatibility and are very well tolerated upon in vivo administration .